Aetion
New York
About Aetion
Aetion delivers real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies, payers, and at-risk providers. With its patented rapid-cycle analytics technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in inpatient care. Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, Greenspring Associates, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Amgen Ventures, Johnson & Johnson Innovation ’ JJDC, Inc., UCB, and Horizon Health Services, Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $1K – $10K
- Total funding: $203.6M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2025)
- Website: aetion.com
- Phone: 646-202-9767
Industries & Categories
Analytics, Health Care, Software
Social Profiles
Canonical: https://fsome.com/organization/aetion-105995 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.